XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash Flows from Operating Activities    
Net income $ 5,085 $ 4,767
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization 597 473
Depreciation 502 511
Income from investments in equity securities, net (90) (143)
Charge for research and development asset acquisition 0 656
Deferred income taxes (186) (51)
Share-based compensation 195 176
Other 109 83
Net changes in assets and liabilities (3,712) (3,382)
Net Cash Provided by Operating Activities 2,500 3,090
Cash Flows from Investing Activities    
Capital expenditures (1,328) (861)
Purchases of securities and other investments (595) (15)
Proceeds from sales of securities and other investments 456 260
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired 0 (746)
Other (20) (14)
Net Cash Used in Investing Activities (1,487) (1,376)
Cash Flows from Financing Activities    
Payments on debt (2,500) (751)
Dividends paid to stockholders (2,050) (1,950)
Purchases of treasury stock (1,164) (122)
Proceeds from exercise of stock options 19 87
Other (60) (78)
Net Cash Used in Financing Activities (5,755) (2,814)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 156 (138)
Net Decrease in Cash, Cash Equivalents and Restricted Cash (4,586) (1,238)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $76 and $68 at January 1, 2025 and 2024, respectively, included in Other current assets) 13,318 6,909
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $103 and $92 at March 31, 2025 and 2024, respectively, included in Other current assets) $ 8,732 $ 5,671